Protagenic Therapeutics, Inc. (NASDAQ:PTIX) Short Interest Update

Protagenic Therapeutics, Inc. (NASDAQ:PTIX) was the recipient of a significant drop in short interest in August. As of August 31st, there was short interest totalling 10,000 shares, a drop of 30.1% from the August 15th total of 14,300 shares. Based on an average daily trading volume, of 39,700 shares, the days-to-cover ratio is presently 0.3 days. Approximately 0.3% of the company’s shares are short sold.

Protagenic Therapeutics Stock Performance

Shares of NASDAQ PTIX traded up $0.01 during trading on Monday, hitting $0.80. 233,426 shares of the company were exchanged, compared to its average volume of 90,683. The company has a fifty day moving average price of $0.70 and a 200-day moving average price of $1.08. The firm has a market capitalization of $3.56 million, a PE ratio of -0.58 and a beta of 0.26. Protagenic Therapeutics has a 12-month low of $0.50 and a 12-month high of $1.98.

Protagenic Therapeutics (NASDAQ:PTIX) last issued its earnings results on Wednesday, August 14th. The company reported ($0.36) EPS for the quarter.

Protagenic Therapeutics Company Profile

Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. The company's lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.